金沙中國(01928.HK)擬贖回全部2025年票據
金沙中國(01928.HK)公佈,擬於今年6月11日(美國時間)根據2025年票據契約之條款及條件,行使其選擇權贖回全部2025年票據。
公司擬提取其2024年SCL定期貸款融資及/或利用其內部現金資源,以爲上述贖回提供資金。2025年票據將按相等於將贖回2025年票據本金額100%,另加截至贖回日期的應計未付利息的贖回價贖回。
截至昨日(22日)營業時間結束時,已發行2025年票據的未償付本金總額爲16.3億美元。票據全部贖回後,將不再有未償付2025年票據。因此,公司將向聯交所申請將該票據於被贖回後自聯交所除牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.